MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) provided an update today on the progress of two early clinical programs from its diabetes and obesity R&D operations. Phase I clinical trial data on both PSN821 and PSN602 showed positive evidence of clinical activity, and both candidates are now progressing to the next stage of clinical development. PSN821 completed a single dose Phase I trial in healthy volunteers and diabetes patients, where evidence of glucose lowering was seen in response to a standard nutrient challenge. PSN602 completed a Phase I trial, where indications of activity in the form of significant reductions in food intake in standardized meal intake assessments were seen after 14 days of dosing in overweight/obese subjects. PSN821, an oral GPR119 agonist being developed for the treatment of type 2 diabetes and PSN602, an oral dual monoamine reuptake inhibitor and 5-HT1A agonist being developed for the treatment of obesity, were discovered by OSI’s diabetes and obesity R&D team and are wholly owned by OSI. Full data from the PSN602 Phase I trial will be presented at a scientific meeting in the second half of 2009.
